Amgen (AMGN) has been in focus after positive Phase 3 data for IMDELLTRA in extensive stage small cell lung cancer and Tezspire in eosinophilic esophagitis, alongside analysts lifting near term earnings expectations.
Recent news has landed in a period of strong momentum for Amgen, with the share price up 10.56% over the past month and 42.23% year to date. The 1-year total shareholder return of 60.49% highlights how recent drug data, dividend declarations and board changes are feeding into a much stronger long term picture for investors.
Scan how Amgen's momentum compares with other large pharmaceutical and biotech stocks by reviewing the hand-picked 30 resilient stocks with low risk scores now that sentiment is tilting toward resilient compounders.
Amgen's surge, fresh late stage data and a full year shareholder return above 60% set a clear tension. Do you pay up after this run, or wait and hope for a friendlier valuation reset?
Most Popular Narrative: 29.5% Overvalued
Against a last close of $466.01 for Amgen, the most followed narrative pegs fair value at $359.98. This frames the current obesity story as far richer than the underlying fundamentals.
The "Amgen 2027 Bull Case" relies on a classic top-line fallacy: assuming that macro obesity market growth and FDA's CNPV (Commissioner's National Priority Voucher) tailwinds will automatically trigger a re-rating.
Here is the cold, data-driven reality:
1. CNPV addresses regulatory speed but not the manufacturing bottleneck. Amgen lacks the massive, domestic GLP-1 supply chain infrastructure that Lilly and Novo command. Fast-tracked approval without scale-up capacity only accelerates market-share caps.
See why 7 investors see Amgen as 29% overvalued .
Result: Fair Value of $359.98 (OVERVALUED)
Still, Amgen could surprise skeptics if MariTide manufacturing scales faster than feared or if legacy therapies stabilize instead of eroding as sharply as critics expect.
Find out about the key risks to this Amgen narrative .
Another View: SWS DCF Model Flags Undervaluation
That user narrative marks Amgen as 29.5% overvalued at $466.01 versus a $359.98 fair value, yet the SWS DCF model points in the opposite direction. On that framework, the shares trade 34.7% below an estimated future cash flow value of $714.04, which puts the current quote nearer to a discount than a premium.
Both lenses cannot be right at the same time. Consider which set of assumptions feels closer to how you think Amgen will actually execute over the next decade, not just the next product cycle.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Amgen for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 29 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals on Amgen's value can either paralyze you or push you to interrogate the numbers yourself. To weigh both the upside and the concerns side by side, start with 4 key rewards and 1 important warning sign .
Looking for more investment ideas beyond Amgen?
If Amgen has sharpened your appetite for opportunities, do not stop here. Broader research across high quality watchlists can help round out your portfolio.
-
Target resilience in tougher markets by reviewing the 30 resilient stocks with low risk scores that aim to keep portfolio swings in check.
-
Hunt for quality at a discount by scanning the 29 high quality undervalued stocks that blend solid fundamentals with attractive pricing.
-
Strengthen your income stream by assessing the 5 dividend fortresses that focus on higher yields with robust backing.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AMGN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
